DDInter1324 DDInter1676
Ofatumumab is a novel anti-CD20 monoclonal antibody that targets B-cells. It is an IgG1κ human monoclonal antibody produced from a recombinant murine cell line (NS0) via transgenic mouse and hybridoma technology. Ofatumumab works by recognizing antigens that are expressed on the tumour cells in certain cancers; however, the antigen is not tumour-specific and can also be found in normal B-cells. Ofatumumab was first approved by the FDA in 2009. It is used in the treatment of recurrent, progressive, or recurrent chronic lymphocytic leukemia (CLL) or CLL in treatment-naive patients in whom fludarabine-based therapy is considered inappropriate. Ofatumumab is used as monotherapy or in combination with other medications, depending on the patient profile and previous treatment history. Although it has a similar molecular mechanism of action as [rituximab], another CD-
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Ofatumumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ocrelizumab
Ofatumumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Topotecan
Ofatumumab {u} may lead to a major life threatening interaction when taken with {v} Teriflunomide
Ofatumumab {u} may lead to a major life threatening interaction when taken with {v} Etanercept
Ofatumumab may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab
Ofatumumab may cause a moderate interaction that could exacerbate diseases when taken with Topotecan
Ofatumumab may lead to a major life threatening interaction when taken with Teriflunomide
Ofatumumab may lead to a major life threatening interaction when taken with Etanercept